CHAIN         1    198       Cyclin-dependent kinase inhibitor 1B.
                             /FTId=PRO_0000190084.
MOTIF       153    169       Nuclear localization signal (Potential).
MOD_RES      10     10       Phosphoserine; by UHMK1.
MOD_RES      74     74       Phosphotyrosine; by SRC.
MOD_RES      88     88       Phosphotyrosine; by ABL, LYN, SRC and
                             JAK2.
MOD_RES      89     89       Phosphotyrosine.
MOD_RES     140    140       Phosphoserine.
MOD_RES     157    157       Phosphothreonine; by PKB/AKT1 and PIM1.
MOD_RES     187    187       Phosphothreonine; by PKB/AKT1 and CDK2.
MOD_RES     198    198       Phosphothreonine; by PKB/AKT1, RPS6KA1,
                             RPS6KA3 and PIM1.
VARIANT      15     15       R -> W (in dbSNP:rs2066828).
                             /FTId=VAR_011871.
VARIANT      69     69       P -> L (found in a patient with multiple
                             endocrine tumors; germline mutation;
                             reduced expression levels; shows impaired
                             binding to CDK2).
                             /FTId=VAR_064429.
VARIANT     109    109       V -> G (in dbSNP:rs2066827).
                             /FTId=VAR_011872.
MUTAGEN      10     10       S->A: Loss of phosphorylation by UHMK1.
                             No translocation to the cytoplasm.
                             Greater cell cycle arrest.
MUTAGEN      10     10       S->D: Exported to the cytoplasm. Inhibits
                             cell cycle arrest.
MUTAGEN      10     10       S->E: Increased stability in vivo and in
                             vitro.
MUTAGEN      74     74       Y->F: No change in binding CDK4 and no
                             inhibition of CDK4 activity. Translocates
                             to nucleus. No effect on in vitro
                             phosphorylation of CDK4 by CCNH-CDK7.
MUTAGEN      88     88       Y->F: Abolishes LYN-mediated
                             phosphorylation, reduceS CDK2-mediated
                             phosphorylation on T-187, has greater
                             cell cycle arrest into S-phase, no effect
                             on binding CDK2 complexes, reduced CDK4
                             binding and inhibits CDK4 enzyme
                             activity. No nuclear translocation. No
                             effect on in vitro phosphorylation of
                             CDK4 by CCNH-CDK7. Completely abolishes
                             CDK4 binding; when associated with F-89.
MUTAGEN      89     89       Y->F: No effect on binding CDK2
                             complexes, reduced CDK4 binding and
                             greatly inhibits CDK4 enzyme activity. No
                             nuclear translocation. Inhibits in vitro
                             phosphorylation of CDK4 by CCNH-CDK7.
                             Completely abolishes CDK4 binding; when
                             associated with F-88.
MUTAGEN     157    157       T->A: Greatly reduced PKB/AKT1-mediated
                             phosphorylation. Nuclear location.
                             Inhibits cyclin E/CDK2 cell cycle
                             progression. No effect on binding AKT1.
                             Completely abolishes PKB/AKT1-mediated
                             phosphorylation and no cytoplasmic
                             translocation; when associated with A-
                             198.
MUTAGEN     161    161       S->A: No change in PKB/AKT1-mediated
                             phosphorylation.
MUTAGEN     162    162       T->A: No change in PKB/AKT1-mediated
                             phosphorylation.
MUTAGEN     185    185       E->A,D,Q: Strongly reduced ubiquitination
                             by a TRIM21-containing SCF(SKP2) complex.
MUTAGEN     187    187       T->A,D: No change in PKB/AKT1- nor UHMK1-
                             mediated phosphorylation.
MUTAGEN     187    187       T->A: Abolishes phosphorylation-dependent
                             ubiquitination.
MUTAGEN     198    198       T->A,D: Abolishes PKB/AKT1-mediated
                             phosphorylation. 46% cytoplasmic
                             location. Greatly reduced binding to
                             YWHAQ. Equally reduced binding; when
                             associated with A-10 and A-187. No
                             nuclear import; when associated with A-
                             157. Completely abolishes PKB/AKT1-
                             mediated phosphorylation and no
                             cytoplasmic translocation; when
                             associated with A-157.
CONFLICT     22     22       E -> D (in Ref. 2; AAD14244).
HELIX        38     49
TURN         50     53
HELIX        54     60
TURN         64     67
STRAND       71     74
STRAND       77     80
HELIX        86     89
Back to Top